above, as well as regulatory changes requiring a modification to our global compensation plan towards the end of  2002 ,  which was disconcerting to our distributor leaders in this market.  Greater China.  The following table sets forth revenue for the Greater China region and its principal markets: Revenue in Greater China increased primarily as a result of the expansion of operations in China. Foreign currency  fluctuations from  2002  to  2003  did not have a notable impact on this region. Revenue in China was $ 38 . 5  million in  2003 ,  following our expansion of retail operations and the introduction of Nu Skin branded products in China in January  2003 .  On a sequential basis, revenue in China increased  67 % from the third quarter to the fourth quarter. This growth is attrib- uted to an increased number of preferred customers and employed sales representatives in China. The success of our prod- uct launches and product promotions as well as our employment opportunities provide an attraction to many unemployed  or underemployed sales people in China. As our business expands in China, we have experienced government scrutiny due  to our international reputation as a direct selling company.  The increase in revenue in China was somewhat offset by the decline in revenue in Taiwan. We believe that the SARS  epidemic negatively impacted revenue in Taiwan and Hong Kong during the first half of  2003 . In addition, revenue in  Taiwan and Hong Kong during the second, third, and fourth quarters of  2002  was positively impacted by distributor en- thusiasm surrounding our planned expansion of operations in China in  2003 . North America.  The following table sets forth revenue for the North America region and its principal markets: The decline in revenue in the United States is principally a result of a $ 22 . 0  million revenue decline in Big Planet in  2003  compared to the prior year. This decline was due primarily to the sale of our professional employer organization and  the restructuring of Big Planet telecommunication products, both of which transitions are part of our continued efforts to  eliminate or modify low margin products. In addition, revenue in  2002  in the United States included $ 6 . 0  million of sales  to foreign distributors during the third quarter of  2002  at the global distributor convention held in the United States, which  did not recur in  2003 . Increasing distributor activity tied to the BioPhotonic Scanner program, a focus on signing up more consumers on  monthly reorder programs, the introduction of new weight management products and implementation of distributor leader- ship incentives, however, resulted in  36 % growth in our Pharmanex revenue in the United States from $ 48 . 3  million in  2002  to $ 65 . 6  million in  2003 , excluding sales to foreign distributors at the  2002  global convention held in the United  States. Nu Skin revenue held relatively constant in  2003  compared to  2002 , excluding sales to foreign distributors at the  same  2002  global convention. Moreover, we experienced an  18 % increase in our  2003  executive distributors in the United  States and a  20 % increase during  2003  of automatic delivery orders compared to  2002 . Early in  2003 , the FDA questioned  the status of the BioPhotonic Scanner as a non-medical device. We believe the BioPhotonic Scanner can be marketed as a  non-medical device, but the FDA has not responded yet to our request to classify the BioPhotonic Scanner as a non-medical  device. In the event the FDA concludes that the BioPhotonic Scanner requires medical device clearance, this could delay or  inhibit our ability to market the BioPhotonic Scanner. We intend to contest any conclusion by the FDA that the BioPho- tonic Scanner is a medical device.  43 2002 2003 Change (U.S. dollars in millions) United States  $  133 . 3 $  118 . 2 (11%) Canada  9 . 4 9 . 4 — North America total $  142 . 7 $  127 . 6 (11%) 2002 2003 Change (U.S. dollars in millions) Taiwan $  78 . 9 $  73 . 1 (7%) China 2 . 0 38 . 5 1,825% Hong Kong 24 . 0 23 . 9 — Greater China total $  104 . 9 $  135 . 5 29%